The Ministry of Food and Drug Safety (Minister Oh Yoo-gyeong) announced on the 9th that it had approved Monjuvi, an orphan drug used to treat diffuse large B-cell lymphoma. For adult patients with relapsed or refractory diffuse large B-cell lymphoma who are unsuitable for autologous hematopoietic stem cell transplantation and who have failed one or more prior therapies, use this drug in combination with lenalidomide, and then use it as monotherapy.

Monjuvi provides a new treatment opportunity for diffuse large B-cell lymphoma by binding to CD19, a B-cell surface antigen protein, and inducing direct apoptosis, antibody-dependent phagocytosis, and antibody-dependent cell-mediated cytotoxicity, resulting i